ArticleJournal of cellular and molecular medicine2019

Targeting EZH2 as a novel therapeutic strategy for sorafenib-resistant thyroid carcinoma.

Zhengshi Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.